Evotec : Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
April 23, 2021 at 07:07 am EDT
Share
DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous
Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
23-Apr-2021 / 13:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014.
Contact:
Dr Werner Lanthaler, Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg, Germany
23-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone:
+49 (0)40 560 81-0
Fax:
+49 (0)40 560 81-222
E-mail:
info@evotec.com
Internet:
www.evotec.com
ISIN:
DE0005664809
WKN:
566480
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.